MDACC Study No:2013-0001 ( NCT No: NCT01907815)
Title:A Phase II Study of MEK 1/2 Inhibitor Trametinib in Combination with AKT Inhibitor GSK2141795 in Acute Myeloid Leukemia (AML) with RAS Mutations
Principal Investigator:Nitin Jain
Treatment Agent:GSK2141795; Trametinib
Study Status:Closed
Study Description:The goal of this clinical research study is to learn if a combination of
trametinib and GSK2141795 can help to control AML. The highest tolerable dose
level as well as the safety of the drugs will also be studied.

Trametinib is designed to block MEK proteins, and GSK2141795 is designed to
block AKT proteins. These proteins cause cancer cells to grow and multiply.
Blocking these proteins may possibly cause the cancer cells to die.

The combination of trametinib and GSK2141795 being used to treat AML with RAS
mutations is considered experimental.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase II
Treatment Agents:GSK2141795
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:MD Anderson Cancer Center
National Cancer Institute
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Nitin Jain
For Clinical Trial Enrollment:713-794-1628
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults